Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of radiation therapy oncology group (RTOG) 83-02
Kevin Murray(The University of Western Australia), Walter J. Curran(Piedmont Cancer Institute), A.Jennifer Fischbach(LDS Hospital), Arthur T. Porter(Wayne State University), Diana F. Nelson(Highland Hospital), Charles Scott(American College of Radiology), Nancy Farnan(RTOG Foundation)
International Journal of Radiation Oncology*Biology*Physics
February 1, 1995
Cited by 60
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k